Ani Pharmaceuticals, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$4.9Mgeneral payments (2019-2025)
$17Kresearch payments (2019-2025)
17,790clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $27.59
2021 $19K
2022 $380K
2023 $839K
2024 $1.1M
2025 $2.5M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Rheumatology $1.3M
Ophthalmology $668K
Nephrology (Internal Medicine) $624K
Neurology (Psychiatry & Neurology) $423K
Pulmonary Disease $350K
Family $264K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Sudhakar Tumuluri San Francisco, CA Rheumatology $190,993.10
Dhiman Basu Colleyville, TX Rheumatology $125,929.81
Wassim Saikali Beckley, WV Rheumatology $97,259.14
Francis Mah Pittsburgh, PA $79,069.98
Sanjay Chabra El Paso, TX Rheumatology $73,112.97
Jessica Coleman Beaufort, SC Nephrology (Internal Medicine) $73,002.32
Rajkumar Dasgupta Pasadena, CA Pulmonary Disease $67,561.24
Kostas Botsoglou Cheektowaga, NY Rheumatology $67,422.22
Andrew Sulich Saint Clair Shores, MI Rheumatology $67,225.68
Regina Berkovich West Hollywood, CA Neurology (Psychiatry & Neurology) $64,730.98

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.